Drug discovery market exclusivity after KSR:The challenge to pharmaceutical scientists and the US congress

The Hatch-Waxman Act provides 180 days of market exclusivity to encourage generic companies to challenge the validity of pharmaceutical patents issued to innovator pharmaceutical companies. The consequent patent losses have been exacerbated owing to the application of holdings of the 2007 Supreme Court KSR decision to questions of pharmaceutical patentability by the judiciary and the US Patent Office. The resulting negative effect on support for new drug and formulation discovery by pharmaceutical scientists is discussed. To counteract the societal detriment of this negative effect, the adoption of a 12‐year US Food and Drug Administration (FDA) market exclusivity paradigm for all approved new chemical entities including prodrugs is proposed. Such market exclusivities have already been enacted in the United States for follow‐on biologicals and are in substantial harmony with those of the European Union, Japan, and Canada. An extension of the existing 3‐year FDA market exclusivity for new formulations under 21 U.S.C. (United States Code) §505(b)(2) to 5 years should also be considered. © 2011 Wiley‐Liss, Inc. and the American Pharmacists Association J Pharm Sci 100:3044-3054, 2011